Two studies evaluating the use of anti–vascular endothelial growth factor injections for eye diseases found payments by Regeneron Pharmaceuticals and Genentech were associated with a higher likelihood of using aflibercept or ranibizumab, respectively, vs lower cost, off-label bevacizumab.10,35 Studies of the impact of industry payments on urologists or oncologists treating prostate cancer reveal similar patterns.6,36,37. This evidence concerns the gene VEGFA and prostate carcinoma.